Trump claims world’s lowest drug prices. TrumpRx discounts are a ‘mixed bag,’ report shows.

This version of Trump Lowest Drug Prices Trumprx Discounts Report Rcna600716 - Health and Medicine | NBC News Clone was adapted by NBC News Clone to help readers digest key facts more efficiently.

A recent analysis of TrumpRx.gov finds prices for certain brand-name drugs can be hit or miss.
Get more newsTrump Lowest Drug Prices Trumprx Discounts Report Rcna600716 - Health and Medicine | NBC News Cloneon

Ahead of the Nov. 3 midterm elections, President Donald Trump has increasingly touted his drug pricing deals, claiming the U.S. is now paying the world’s lowest prescription drug prices. “This one thing alone should win us the midterms,” he recently said at the White House.

TrumpRx.gov, the public face of his drug pricing discounts, has grown dramatically since its launch in February. What started as a few dozen brand-name drugs now includes a catalog of more than 800 brand-name and generic medications, offering discounts on everything from popular weight loss drugs to treatments for cancer and rheumatoid arthritis.

It’s unclear whether the average American has “saved a fortune,” as Trump promised.

Prescription drug prices fell by 3.1% over the year ending in July, according to federal inflation data — though experts say it’s too soon to know how much of the drop, if any, can be attributed to Trump’s drug pricing deals. The site has relied on GoodRx’s pricing data and technology to power many of its listings and blends pre-existing discounts from drugmakers with newly negotiated prices.

At the Republican midterm convention last month, Trump said, “We went from the highest prescription drug prices, by far, anywhere in the world, to the lowest prescription drug prices anywhere in the world.”

A recent analysis from KFF finds that TrumpRx prices are competitive with prices in other countries for a small number of cancer and cholesterol medications. In many cases, Americans aren’t getting the best deals compared with the rest of the world.

Take Ozempic. For the average patient in the U.S. paying out of pocket, the blockbuster diabetes drug can cost $349 to more than $1,000 a month. It’s $349 through TrumpRx. Yet in several other wealthy countries, the next-highest price is $190 a month, according to KFF, a nonpartisan research group.

Enbrel is an even starker example. A monthly supply of the rheumatoid arthritis drug costs $3,354 through TrumpRx, more than five times the $641 average in the other countries where researchers found prices.

Some drugs, however, come out well ahead. Rydapt, a drug used to treat certain blood cancers, costs $2,909 for 56 capsules through TrumpRx — less than half the $5,901 price for the same amount in France, the next-cheapest country.

Those disparities run throughout the site, according to the KFF analysis. The report, which didn’t compare TrumpRx savings within the U.S., offers one of the first broad worldwide comparisons of Trump’s drug pricing claims.

The analysis looked at 32 brand-name drugs sold through TrumpRx that lacked generic or biosimilar equivalents. Researchers focused on those drugs because patients don’t have the option of switching to cheaper versions, meaning the discounts offered through TrumpRx could have a greater impact on what they pay.

The group compared the prices with those in 11 other wealthy countries, including Canada, France, Germany, the Netherlands and the United Kingdom. The prices are current as of Aug. 26.

The results were almost evenly split. For 17 of the drugs, the TrumpRx prices were lower than the average prices abroad. For 15, they were higher. But Trump has promised Americans the lowest prices in the world. By that measure, the results were less favorable: Only five were actually the lowest-priced, while 13 were the highest-priced.

“It’s kind of a mixed bag,” said Juliette Cubanski, deputy director of the Medicare policy program at KFF, who co-authored the report. “Even with the reductions that may have been agreed to by manufacturers who are listing their drugs on the TrumpRx website, the prices that they’re offering, even at a discount, still continue to be higher than prices in comparable countries.”

Drug price discounts vary widely

The findings offer an early look at both the promise and the limits of Trump’s approach to lowering drug prices.

Americans routinely pay more for prescription drugs than patients in other wealthy countries, even when the medications are made by the same companies. The TrumpRx discounts, the White House says, stem from Trump’s “most favored nation” pricing deals, agreements with drugmakers to charge Americans the lower prices they offer other countries in exchange for tariff relief. But the discounts can vary widely, the analysis found, and they haven’t consistently produced the lowest prices Trump promised.

“I’m not surprised by these findings,” said Dr. Benjamin Rome, a primary care physician and health policy researcher at Harvard Medical School. “Any of us who have been following drug prices realized, as soon as TrumpRx was launched, it was a limited number of drugs and it was clear that the prices that were there were not always going to be linked or in any way related to what the prices are in other countries.”

It’s a markedly different approach from the one taken by Trump’s predecessor Joe Biden.

Rather than use Medicare’s power to negotiate prices for a limited number of costly drugs each year, TrumpRx relies largely on voluntary agreements with individual drugmakers to offer discounted prices directly to consumers. (The exact details of the agreements remain largely confidential, and the White House has declined to disclose them.)

TrumpRx doesn’t sell the drugs directly. For many drugs, it sends consumers to manufacturer programs through which they can obtain coupons or discounted cash prices without insurance.

That’s not how most people get their prescription drugs. About 9 in 10 Americans have some form of health insurance, meaning many pay for medications through private insurance, Medicare or Medicaid — although discounted cash-pay options have become increasingly popular as insurance has gotten more expensive. The money spent on TrumpRx doesn’t count toward a patient’s copay or deductible.

“They’re highly selected products where the manufacturer is willing to offer a discount,” Rome said. “Maybe they’re not the products causing the highest spending in the U.S. in some cases or are products where they were already offering confidential discounts, but now they’re making those discounts more public.”

The site now includes several cheaper, generic medications. “But those generics and the low prices for those generics pre-existed the TrumpRx website,” Cubanski said.

Direct price comparisons are difficult

The KFF analysis doesn’t capture every drug available through TrumpRx, and there are limits to how much can be concluded from it.

Antonio Ciaccia, CEO of 46brooklyn Research, a group that tracks drug pricing in the U.S., counts about 80 brand-name drugs currently on TrumpRx, while KFF was able to compare prices for 32.

Part of the challenge, Ciaccia said, is that some drugs sold in the U.S. aren’t available in all of the countries KFF examined. That can make direct comparisons difficult.

“One of the big differences is the U.S. market does have more products in it than international markets, so that is noteworthy to the extent we have options here in the U.S. rather than a one-size-fits-all treatment approach,” he said.

International prices aren’t always perfectly comparable, either, he said. The analysis relied on publicly available prices, which may not include confidential discounts negotiated between foreign governments and drugmakers.

Ciaccia also noted that KFF’s 11 comparison countries don’t exactly match the countries used in some of the administration’s international pricing programs.

A White House spokesperson referred NBC News to the Centers for Medicare & Medicaid Services for comment. The CMS didn’t immediately respond to a request for comment.

Put the claim to the test

Those limitations don’t change the basic comparison at the heart of Trump’s claim: whether the prices offered to Americans match or beat those available abroad.

“We wanted to put that claim to the test with this analysis,” Cubanski said. “There is not a clear pattern across the board for higher prices or no consistent pattern across the board for lower prices.”

And the administration has increasingly made broader claims that it has accomplished just that.

“Over the past year, my administration has reached unprecedented agreements with 26 of the world’s largest pharmaceutical companies, and the rest are all coming in very rapidly, to provide their drugs to Americans at discounts of 60, 70, 80 and even 90% discount,” Trump said last month.

Health policy experts hope TrumpRx will ultimately bring U.S. prices down, but they say it’s too soon to know. A concern, however, is that as more drugmakers strike deals, they could also raise prices abroad, narrowing the gap without delivering Americans savings.

“It’s not just that the price in the U.S. might come down, but another way of having a lower U.S. price is by having a higher international price, and so it could be the case that if we do this comparison again in a year, we might find that TrumpRx are lower than international prices,” Cubanski said.

AdBlock Detected!
Please disable it to support our content.
×

Related Articles

Donald Trump Presidency Updates - Politics and Government | NBC News Clone | Joe Biden Campaign News - Politics and Government | NBC News Clone | Kamala Harris Vp Announcement - Politics and Government | NBC News Clone | Trump Indictment Latest - Politics and Government | NBC News Clone | Election Results Live - Politics and Government | NBC News Clone | Swing States Polling - Politics and Government | NBC News Clone | Debate Highlights - Politics and Government | NBC News Clone | Budget Approval 2025 - Politics and Government | NBC News Clone | Abortion Ruling - Politics and Government | NBC News Clone | Us China Relations - Politics and Government | NBC News Clone | Inflation Rates 2025 Analysis - Business and Economy | NBC News Clone | Federal Reserve Interest Rates - Business and Economy | NBC News Clone | Stock Market Today - Business and Economy | NBC News Clone | Recession Prediction 2025 - Business and Economy | NBC News Clone | Jobs Report Unemployment - Business and Economy | NBC News Clone | Ai Stock Surge - Business and Economy | NBC News Clone | Housing Market Crash - Business and Economy | NBC News Clone | Oil Prices Update - Business and Economy | NBC News Clone | Amazon Prime Sales - Business and Economy | NBC News Clone | Bitcoin Etf Approval - Business and Economy | NBC News Clone | Latest Vaccine Developments - Health and Medicine | NBC News Clone | Covid Variants Update - Health and Medicine | NBC News Clone | Boosters New Guidelines - Health and Medicine | NBC News Clone | Anxiety Depression Treatment - Health and Medicine | NBC News Clone | Longevity Research - Health and Medicine | NBC News Clone | Diet Trends 2025 - Health and Medicine | NBC News Clone | Workout Routines - Health and Medicine | NBC News Clone | Fda Approvals 2025 - Health and Medicine | NBC News Clone | Ukraine Russia Conflict Updates - World News | NBC News Clone | Israel Palestine War News - World News | NBC News Clone | China Taiwan Tensions - World News | NBC News Clone | Middle East Peace Talks - World News | NBC News Clone | European Union Politics - World News | NBC News Clone | Development News - World News | NBC News Clone | North Korea Missile Test - World News | NBC News Clone | Brazil Election - World News | NBC News Clone | Openai Chatgpt News - Technology and Innovation | NBC News Clone | Google Bard Ai - Technology and Innovation | NBC News Clone | Ai Regulation Laws - Technology and Innovation | NBC News Clone | Tiktok Ban Update - Technology and Innovation | NBC News Clone | Data Breaches 2025 - Technology and Innovation | NBC News Clone | Iphone 16 Release - Technology and Innovation | NBC News Clone | Nasa Mars Mission - Technology and Innovation | NBC News Clone | Web3 Developments - Technology and Innovation | NBC News Clone | 2024 Paris Games Highlights - Sports and Recreation | NBC News Clone | Super Bowl 2025 Preview - Sports and Recreation | NBC News Clone | Nba Playoffs 2025 - Sports and Recreation | NBC News Clone | Champions League Finals - Sports and Recreation | NBC News Clone | World Series 2025 - Sports and Recreation | NBC News Clone | Masters Tournament 2025 - Sports and Recreation | NBC News Clone | Extreme Weather Events - Weather and Climate | NBC News Clone | Hurricane Season 2025 - Weather and Climate | NBC News Clone | Global Warming Report - Weather and Climate | NBC News Clone | Weekly Weather Update - Weather and Climate | NBC News Clone | Earthquake Alerts - Weather and Climate | NBC News Clone | Solar Storm Warning - Weather and Climate | NBC News Clone | Hollywood Updates - Entertainment and Celebrity | NBC News Clone | Oscar Nominations 2025 - Entertainment and Celebrity | NBC News Clone | Grammy Awards 2025 - Entertainment and Celebrity | NBC News Clone | Netflix New Releases - Entertainment and Celebrity | NBC News Clone | Video Game Releases - Entertainment and Celebrity | NBC News Clone | Bestseller List - Entertainment and Celebrity | NBC News Clone | Government Transparency - Investigations and Analysis | NBC News Clone | Political Corruption - Investigations and Analysis | NBC News Clone | Big Tech Monopoly - Investigations and Analysis | NBC News Clone | Data Privacy Scandal - Investigations and Analysis | NBC News Clone | Community Stories - Local News and Communities | NBC News Clone | Nyc Mayor News - Local News and Communities | NBC News Clone | La Wildfires Update - Local News and Communities | NBC News Clone | Hurricane Preparedness - Local News and Communities | NBC News Clone